We invite all our members and the transplant community as a whole to present their latest research at the Congress. Choose among many submission topics and we are also offering abstract-based awards!
Accepted abstracts will be published in an online supplement of the Transplantation Journal.
This study assessed the ability of T cells to react with Omicron spike in participants who were vaccinated with Ad26.CoV2.S, BNT162b2, or unvaccinated convalescent COVID-19 patients. It shows that 70-80% of the CD4+ and CD8+ T cell response to spike was maintained across study groups. Moreover, the magnitude of Omicron cross-reactive T cells was similar to Beta and Delta variants, despite Omicron harboring considerably more mutations. This, despite Omicron’s extensive mutations and reduced susceptibility to neutralizing antibodies, the majority of T cell responses, induced by vaccination or infection, cross-recognize the variant.
This study shows that that the primary two-dose regimen of the mRNA-1273 vaccine elicited detectable neutralizing antibodies against the omicron variant in 85% of the participants 1 month after the second dose. The booster dose was associated with ID50 geometric mean titers against the omicron variant that were 20.0 times higher than those assessed 1 month after the second vaccination; these titers were 2.9 times lower than those against the D614G variant. Six months after the booster, neutralization titers against the omicron variant declined faster than those against the D614G variant; however, this decline in titers against the omicron variant was similar to the decline observed in titers against the D614G variant after a second dose of the mRNA-1273 vaccine
This is a single center, single-blinded, 1:1 randomized clinical trial of a third dose of vaccine against SARS-CoV-2, conducted from June 15 to August 16, 2021, in 201 KTRs who had not developed SARS-CoV-2 spike protein antibodies after 2 doses of an mRNA vaccine. Among the study population of 197 kidney transplant recipients (mean [SD] age, 61.2 [12.4] years; 82 [42%] women), 39% developed SARS-CoV-2 antibodies after the third vaccine. Only 22% of seroconverted patients had neutralizing antibodies. Similarly, T-cell response assessed by IGRA was low with only 17 patients showing a positive response after the third vaccination.
In 2022, two Officer positions will be vacated and 5 of the 12 Councilors-at-large representing the Regions will be changing. The elections will take place early in 2022 and those elected will assume their new roles starting at the 2022 TTS Congress in Buenos Aires.
Members can access the online nominating form at www.tts.org/nominations. Since each nominee must have his or her form signed by three supporting members (including him/herself), the online process allows for efficient and rapid circulation.
For more information on elections, visit the TTS website and consult the By-Laws in the “About” section.
Recognized as the world's highest dedicated award for the most outstanding contributions in the field of transplantation.
THE INTERNATIONAL TRANSPLANTATION SCIENCE MENTEE-MENTOR AWARDS FOR THE 29TH INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY (TTS 2022) – BUENOS AIRES, ARGENTINA, SEPTEMBER 10-14, 2022.
The Transplantation Society celebrates the contributions of basic science to the field of transplantation with the International Transplantation Science Mentee-Mentor Awards to recognize the efforts of scientists who have advanced our understanding of transplantation science and fostered the development of the young investigators who will be the future leaders in our field.
The application will open in January 2022. Deadline for submission is April 10, 2022.Click here for more details